A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
25actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-03 | actual | When the study began enrolling |
| Primary completion | 2025-06-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: PF-07941944
- Drug: Placebo
- Drug: Midazolam
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
measured Baseline through end of study, approximately 16 weeks
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
measured Baseline through end of study, approximately 16 weeks
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
measured Baseline through end of study, approximately 16 weeks
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings
measured Baseline through end of study, approximately 16 weeks
Maximum Observed Plasma Concentration (Cmax)
measured Baseline through end of study, approximately 16 weeks
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
measured Baseline through end of study, approximately 16 weeks
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
measured Baseline through end of study, approximately 16 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed